Zanidip 10mg Tablets

  • Name:

    Zanidip 10mg Tablets

  • Company:
    info
  • Active Ingredients:

    Lercanidipine Hydrochloride

  • Legal Category:

    Product subject to medical prescription which may be renewed (B)

Summary of Product Characteristics last updated on medicines.ie: 18/8/2017
print

Print ViewKeyword Search SmPC

Recordati Ireland Limited

Recordati Ireland Limited

Company Products

Medicine NameActive Ingredients
Medicine Name Betaloc 1 mg/ml Solution for Injection Active Ingredients Metoprolol Tartrate
Medicine Name Citrafleet Active Ingredients Citric Acid (Anhydrous), Magnesium Oxide Light, Sodium picosulfate
Medicine Name Cleenema Ready-to-Use 21.4g / 9.4g Enema Active Ingredients Disodium Phosphate Dodecahydrate, Sodium Dihydrogen Phosphate Dihydrate
Medicine Name Kentera oxybutynin transdermal patch Active Ingredients Oxybutynin
Medicine Name Lercaril 10 mg/10 mg Film-coated Tablets Active Ingredients Enalapril Maleate, Lercanidipine Hydrochloride
Medicine Name Lercaril 20 mg/10 mg Film-coated Tablets Active Ingredients Enalapril Maleate, Lercanidipine Hydrochloride
Medicine Name Lercaril 20 mg/20 mg Film-coated Tablets Active Ingredients Enalapril Maleate, Lercanidipine Hydrochloride
Medicine Name Phospho-soda 24.4g / 10.8g oral solution Active Ingredients Disodium Phosphate Dodecahydrate, Sodium Dihydrogen Phosphate Dihydrate
Medicine Name Reagila 1.5 mg hard capsules Active Ingredients Cariprazine hydrochloride
Medicine Name Reagila 3 mg hard capsules Active Ingredients Cariprazine hydrochloride
Medicine Name Reagila 4.5 mg hard capsules Active Ingredients Cariprazine hydrochloride
Medicine Name Reagila 6 mg hard capsules Active Ingredients Cariprazine hydrochloride
Medicine Name Urispas 200mg film-coated tablets Active Ingredients Flavoxate Hydrochloride, Lactose
Medicine Name Urorec 4 mg capsules Active Ingredients Silodosin
Medicine Name Urorec 8 mg capsules Active Ingredients Silodosin
Medicine Name Urorec capsules Active Ingredients Silodosin
Medicine Name Vitaros 3mg/g Cream Active Ingredients Alprostadil
Medicine Name Zanidip 10mg and 20mg Tablets Active Ingredients Lercanidipine Hydrochloride
Medicine Name Zanidip 10mg Tablets Active Ingredients Lercanidipine Hydrochloride
Medicine Name Zanidip 20mg Tablets Active Ingredients Lercanidipine Hydrochloride
1 - 0 of 20 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 18 August 2017 PIL

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

Section 2 - updated to bring it in line with the QRD template
Section 4.2-updated to bring it in line with the QRD template
Section 4.3-updated to bring it in line with the QRD template
Section 4.4-updated to bring it in line with the QRD template
Section 4.5-updated to bring it in line with the QRD template
Section-4.6-updated to bring it in line with the QRD template
Section 4.6-updated to bring it in line with the QRD template
Section 4.7-updated to bring it in line with the QRD template
Section 4.8-updated to bring it in line with the QRD template
Section 4.9-updated to bring it in line with the QRD template
Section 5.1-updated to bring it in line with the QRD template
Section 5.2-updated to bring it in line with the QRD template
section 6.4-updated to bring it in line with the QRD template
Section 6.6-updated to bring it in line with the QRD template
Section 10- date of revision has been updated

Updated on 18 August 2017 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 18 August 2017 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 2 - updated to bring it in line with the QRD template
Section 4.2-updated to bring it in line with the QRD template
Section 4.3-updated to bring it in line with the QRD template
Section 4.4-updated to bring it in line with the QRD template
Section 4.5-updated to bring it in line with the QRD template
Section-4.6-updated to bring it in line with the QRD template
Section 4.6-updated to bring it in line with the QRD template
Section 4.7-updated to bring it in line with the QRD template
Section 4.8-updated to bring it in line with the QRD template
Section 4.9-updated to bring it in line with the QRD template
Section 5.1-updated to bring it in line with the QRD template
Section 5.2-updated to bring it in line with the QRD template
section 6.4-updated to bring it in line with the QRD template
Section 6.6-updated to bring it in line with the QRD template
Section 10- date of revision has been updated

Updated on 15 July 2011 PIL

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.5 - Nature and contents of container
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text
  • Change to section 4.3 - Contraindications
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.2 - Posology and method of administration

Free text change information supplied by the pharmaceutical company

In Section 2 : The word "Contains" was added to excipients
In Section 3 : " The score line is only to faciliate breaking for ease of swallowing and not to divide into equal doses" was added
In Section 4.2 : "There is no experience in children" was added to Experience in Children
In Section 4.3 : " to the active substance" was deleted and "hydrochloriode" was added in the first sentence
In Section 4.5 : "Interaction studies have only been performed in adults" was added
In Section 4.8 : "WHO ART Body System" was deleted and "MedRA System Organ Class" was added. The Undesirable Effects table was revised to be in line with MedRA Terms
In Section 4.9 : The Overdose Data was updated to include the 3rd case reported of overdose and a table was inserted to summarise experience of overdose thus far
In Section 5.2 : The following headings were added: Distribution, Biotransformation, Elimination, Linearity/Non-Linearity, Characteristics in Patients
In Section 5.3 : "Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction." was inserted
In Section 6.4 : "In order to protect from light and moisture" was added
In Section 6.5 : Packs of 7, 14 and  28
In Section 6.6 : "Special precautions for disposal of a used medicinal product or waste materials derived from such medicinal product and other handling of the product" added
In Section 9 : "Date of first authorisation" and "Date of last renewal" inserted
In Section 10 : "July 2011" inserted

Updated on 15 July 2011 SmPC

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.5 - Nature and contents of container
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text
  • Change to section 4.3 - Contraindications
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.2 - Posology and method of administration

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In Section 2 : The word "Contains" was added to excipients
In Section 3 : " The score line is only to faciliate breaking for ease of swallowing and not to divide into equal doses" was added
In Section 4.2 : "There is no experience in children" was added to Experience in Children
In Section 4.3 : " to the active substance" was deleted and "hydrochloriode" was added in the first sentence
In Section 4.5 : "Interaction studies have only been performed in adults" was added
In Section 4.8 : "WHO ART Body System" was deleted and "MedRA System Organ Class" was added. The Undesirable Effects table was revised to be in line with MedRA Terms
In Section 4.9 : The Overdose Data was updated to include the 3rd case reported of overdose and a table was inserted to summarise experience of overdose thus far
In Section 5.2 : The following headings were added: Distribution, Biotransformation, Elimination, Linearity/Non-Linearity, Characteristics in Patients
In Section 5.3 : "Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction." was inserted
In Section 6.4 : "In order to protect from light and moisture" was added
In Section 6.5 : Packs of 7, 14 and  28
In Section 6.6 : "Special precautions for disposal of a used medicinal product or waste materials derived from such medicinal product and other handling of the product" added
In Section 9 : "Date of first authorisation" and "Date of last renewal" inserted
In Section 10 : "July 2011" inserted

Updated on 15 August 2006 PIL

Reasons for updating

  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

Section 10: date of revision of text updated.

Updated on 15 August 2006 SmPC

Reasons for updating

  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 10: date of revision of text updated.

Updated on 9 November 2005 PIL

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 6.1 - List of excipients
  • Change to section 6.2 - Incompatibilities
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.5 - Nature and contents of container
  • Change to section 6.6 - Special precautions for disposal and other handling

Updated on 9 November 2005 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 6.1 - List of excipients
  • Change to section 6.2 - Incompatibilities
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.5 - Nature and contents of container
  • Change to section 6.6 - Special precautions for disposal and other handling

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 25 June 2003 PIL

Reasons for updating

  • New SPC for medicines.ie

Updated on 25 June 2003 SmPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Product subject to medical prescription which may be renewed (B)